Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Remyelination in multiple sclerosis

H Lassmann1, W Brück, C Lucchinetti

  • 1Institute of Neurology, University of Vienna, Austria.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Iron Rims in Patients With Multiple Sclerosis as Neurodegenerative Marker? A 7-Tesla Magnetic Resonance Study.

Frontiers in neurology·2022
Same author

PDE10A antibodies in autoimmune encephalitis: A possible marker of cancer immunotherapy?

Neurology·2019
Same author

Pro-inflammatory activation of microglia in the brain of patients with sepsis.

Neuropathology and applied neurobiology·2018
Same author

CNS neuroimmunology seen by a neuropathologist.

Revue neurologique·2014
Same author

TIRC7 and HLA-DR axis contributes to inflammation in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2014
Same author

Microstructural magnetic resonance imaging of cortical lesions in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2012
Same journal

Association of epiretinal membranes with disability in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Epiretinal membranes in multiple sclerosis: A window into glial pathobiology?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

UK consensus on pregnancy in multiple sclerosis: An update to 'Association of British Neurologists' guidance.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Comparative effectiveness of rituximab versus ocrelizumab in relapsing multiple sclerosis on clinical relapses and radiological outcomes in British Columbia, Canada.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same journal

Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
See all related articles

Remyelination therapy for multiple sclerosis (MS) shows promise, but its feasibility depends on patient-specific factors and disease stage. Spontaneous remyelination is more prominent in early MS, highlighting potential therapeutic windows.

Area of Science:

  • Neuroscience
  • Immunology
  • Regenerative Medicine

Background:

  • Multiple sclerosis (MS) is a heterogeneous neuroinflammatory disease characterized by demyelination.
  • Remyelination, the repair of myelin sheaths, is a potential therapeutic strategy for MS.
  • Understanding the factors influencing remyelination is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the feasibility and patient-specific factors influencing remyelination in multiple sclerosis lesions.
  • To analyze the stage-dependent and form-dependent characteristics of remyelination in MS.

Main Methods:

  • Review of existing literature on spontaneous remyelination in multiple sclerosis.
  • Correlation analysis of remyelination extent with oligodendrocyte presence and disease duration.

Related Experiment Videos

  • Comparative analysis of remyelination across different MS subtypes.

    • Main Results:

    • Spontaneous remyelination occurs in some MS patients, correlating with oligodendrocyte presence in lesions.
    • Complete remyelination can lead to the formation of 'shadow plaques'.
    • Remyelination is most prominent in early stages of MS and significantly reduced in later stages and primary progressive MS.

    Conclusions:

    • The potential for remyelination therapy in MS requires careful consideration of disease heterogeneity and stage.
    • Early-stage MS and relapsing-remitting forms may offer better opportunities for therapeutic remyelination.
    • Further research is needed to clarify the origin of remyelinating cells and optimize therapeutic strategies.